Regulatory and clinical considerations for biosimilar oncology drugs
Charles L Bennett, Brian Chen, Terhi Hermanson, Michael D Wyatt, Richard M Schulz, Peter Georgantopoulos, Samuel Kessler, Dennis W Raisch,Zaina P Qureshi, Z Kevin Lu, Bryan L Love, Virginia Noxon, Laura Bobolts, Melissa Armitage, John Bian, Paul Ray, Richard J Ablin,William J Hrushesky, Iain C Macdougall, Oliver Sartor, James O Armitage. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncology; vol 15; Dec. 2014.
Synopsis: In this review, the only review paper on biosimilars not supported by the pharmaceutical industry, the regulatory frameworks, clinical experiences, an....Read Article >>